Search clinical trials for: carbplatin, cyclophophamide, atezolizumab

Total 6998 results

H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Ovarian Cancer | Endometrial Cancer

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower150)

Carcinoma, Non-Small-Cell Lung

United States, Spain, France, Belgium, Australia, Germany, Argentina, Japan, Brazil, Italy, Singapore, Russian Federation, Taiwan, Netherlands, Peru, Chile, Latvia, Ukraine, Mexico, Lithuania, Slovakia, Bulgaria, Portugal, Austria, Swit... and more
Queen Mary University of London
Hoffmann-La Roche

Recruiting

Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer (ABACUS-2)

Urogenital Cancer

United Kingdom
Hoffmann-La Roche

Completed

A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

Urothelial Carcinoma

Argentina
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Carcinoma, Non-Small Cell Lung | Urothelial Carcinoma | Triple Negative Breast Carcinoma

Korea, Republic of
Genentech, Inc.

Terminated

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

Urothelial Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Belgium
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Small Cell Lung Cancer

Poland, Russian Federation, United States, Austria, Canada, Hungary, Israel, Italy, Korea, Republic of, Spain, Switzerland
Seattle Institute for Biomedical and Clinical Research
VA Puget Sound Health Care System; Prostate Cancer Foundation

Terminated

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Duke University
Aventis Pharmaceuticals

Completed

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Ovarian Cancer

United States
Institut Curie
Roche Pharma AG; Replimune Inc.

Not yet recruiting

"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (neoBREASTIM)

Triple Negative Breast Neoplasms

France
Grupo Espanol de Tumores Neuroendocrinos
Roche Pharma AG; Ipsen

Active, not recruiting

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN)

Adenocarcinoma | Neuroendocrine Tumor | Pheochromocytoma | Paraganglioma | Anaplastic Thyroid Cancer

Spain
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1)

Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )

France
Hoffmann-La Roche

Completed

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Colorectal Cancer

Canada, United States, Italy, Korea, Republic of, United Kingdom, Belgium, Russian Federation, Hong Kong, Spain, Australia, Poland
GlaxoSmithKline

Completed

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Neoplasms, Breast

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor

Brain Tumor | Central Nervous System Tumor

United States, Canada, Australia, Puerto Rico
Synlogic
IQVIA Biotech

Recruiting

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects

Lymphoma | Metastatic Solid Neoplasm

United States
Hoffmann-La Roche

Completed

A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Tracon Pharmaceuticals Inc.

Active, not recruiting

Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

Solid Tumor | Metastatic Cancer

United States
Hoffmann-La Roche

Terminated

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Triple Negative Breast Cancer | Advanced Ovarian Cancer

United Kingdom, United States, Australia, Denmark, Canada
Genentech, Inc.

Completed

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Hematologic Malignancies | Tumors

Spain, France, United States, United Kingdom
McGill University Health Centre/Research Institute...

Unknown

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

Safety Issues

Canada
Mothaffar Rimawi

Active, not recruiting

Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer (CADENCE)

Breast Cancer

United States
Shanghai Institute Of Biological Products
Fudan University

Completed

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

HER2-positive Early Breast Cancer

China
Swiss Group for Clinical Cancer Research

Completed

Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Switzerland
Nykode Therapeutics ASA
Roche Pharma AG; GOG Foundation

Recruiting

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Cervical Cancer | HPV-Related Malignancy | HPV-Related Cervical Carcinoma

United States
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Societe Internationale d'Oncologie Pediatrique

Completed

Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS

Brain and Central Nervous System Tumors

United Kingdom
Basilea Pharmaceutica

Completed

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)

Urothelial Carcinoma

United Kingdom, Korea, Republic of, Italy, Canada, France, Spain, Germany, United States, Hungary, Australia, Poland, Switzerland, Czechia, Austria
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; Celgene Corporation

Completed

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

Breast Cancer

United States
Ahmad Tarhini
Novartis Pharmaceuticals

Terminated

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin Melanoma

United States, Australia
Hoffmann-La Roche

Completed

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Spain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
Memorial Sloan Kettering Cancer Center

Completed

Chemotherapy in Treating Patients With Retinoblastoma

Retinoblastoma

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.

Lung Cancer | Carcinoma of Unknown Primary

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Breast Cancer

United States
Daiichi Sankyo
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Extensive Stage-small Cell Lung Cancer
Hoffmann-La Roche
Jazz Pharmaceuticals

Active, not recruiting

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

Small-Cell Lung Cancer

United States, Belgium, Italy, Spain, Turkey, United Kingdom, Korea, Republic of, Germany, Mexico, Hungary, Taiwan, Greece, Poland
Vall d'Hebron Institute of Oncology

Recruiting

Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform (PORTRAIT)

Triple Negative Breast Cancer

Spain
Seattle Children's Hospital
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Beijing Syngentech Co., Ltd.

Not yet recruiting

SynOV1.1 Intratumoral Injection Study

Hepatocellular Carcinoma
Bavarian Nordic

Completed

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Bladder Cancer

United States
Hoffmann-La Roche

Completed

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

Solid Tumors

United States, Denmark, Spain, Canada, France, Italy, Netherlands
University of Michigan Rogel Cancer Center

Terminated

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Urothelial Carcinoma

United States
Niharika Mettu
Roche-Genentech

Withdrawn

Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER)

Metastatic Colorectal Cancer

United States
VA Office of Research and Development

Recruiting

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA)

Metastatic Castrate Resistant Prostate Cancer | BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 | RAD51B, RAD51C, RAD51D, or RAD54L Mutations

United States
The Netherlands Cancer Institute

Active, not recruiting

High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer (Oligo)

Breast Cancer

Netherlands
G1 Therapeutics, Inc.

Completed

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer

United States
Base Therapeutics (Shanghai) Co., Ltd.
The General Hospital of Eastern Theater Command

Recruiting

Safety and Efficacy of NK510 to Treat NSCLC

NSCLC

China
Mateon Therapeutics

Terminated

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer (FACT)

Anaplastic Thyroid Cancer

United States, India, Belarus, Bulgaria, Egypt, Israel, Italy, Poland, Romania, Russian Federation, Ukraine, United Kingdom

Search clinical trials for: carbplatin, cyclophophamide, atezolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations